213 related articles for article (PubMed ID: 34314755)
1. The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma.
Augello G; Emma MR; Azzolina A; Puleio R; Condorelli L; Cusimano A; Giannitrapani L; McCubrey JA; Iovanna JL; Cervello M
Cancer Lett; 2021 Oct; 519():250-262. PubMed ID: 34314755
[TBL] [Abstract][Full Text] [Related]
2. NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Emma MR; Iovanna JL; Bachvarov D; Puleio R; Loria GR; Augello G; Candido S; Libra M; Gulino A; Cancila V; McCubrey JA; Montalto G; Cervello M
Cell Death Dis; 2016 Jun; 7(6):e2269. PubMed ID: 27336713
[TBL] [Abstract][Full Text] [Related]
3. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
[TBL] [Abstract][Full Text] [Related]
4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
6. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
[TBL] [Abstract][Full Text] [Related]
7. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
9. RNA m
Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G
EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828
[TBL] [Abstract][Full Text] [Related]
10. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
Wang D; Yang J
Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
[TBL] [Abstract][Full Text] [Related]
11. Silencing
Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus X promotes hepatocellular carcinoma development via nuclear protein 1 pathway.
Bak Y; Shin HJ; Bak Is; Yoon DY; Yu DY
Biochem Biophys Res Commun; 2015 Oct; 466(4):676-81. PubMed ID: 26392315
[TBL] [Abstract][Full Text] [Related]
13. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
[TBL] [Abstract][Full Text] [Related]
14. Induction of nuclear protein-1 by thyroid hormone enhances platelet-derived growth factor A mediated angiogenesis in liver cancer.
Chen CY; Wu SM; Lin YH; Chi HC; Lin SL; Yeh CT; Chuang WY; Lin KH
Theranostics; 2019; 9(8):2361-2379. PubMed ID: 31149049
[No Abstract] [Full Text] [Related]
15. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
16. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
18. Quantitative proteomics identifies FOLR1 to drive sorafenib resistance via activating autophagy in hepatocellular carcinoma cells.
Chu H; Wu C; Zhao Q; Sun R; Yang K; Zhao B; Liu Y; Liang Z; Zhong S; Zhang L; Zhang Y
Carcinogenesis; 2021 May; 42(5):753-761. PubMed ID: 33677528
[TBL] [Abstract][Full Text] [Related]
19. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
20. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
